Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101738 · ClinicalTrials.gov registry record · Phase 3
Freedom Study: Myfortic in Kidney Transplant Patients
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 342
- Enrollment target
NCT00101738 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 342 participants.
The verdict
NCT00101738, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 342 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.
Interventions
- DRUG Myfortic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101738
The ClinicalTrials.gov registry entry for NCT00101738 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Myfortic is the first listed.
NCT00101738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00101738 about?
NCT00101738 is a clinical study titled "Freedom Study: Myfortic in Kidney Transplant Patients". The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.
What is the current status of trial NCT00101738?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 342 participants. The study started on 2003-03. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00101738?
The interventions under investigation include: Myfortic (DRUG).
Who is sponsoring clinical trial NCT00101738?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.